CIBC Asset Management Inc Sells 9,245 Shares of IQVIA Holdings Inc. (NYSE:IQV)

CIBC Asset Management Inc lowered its position in IQVIA Holdings Inc. (NYSE:IQVFree Report) by 3.6% in the 4th quarter, Holdings Channel reports. The fund owned 245,278 shares of the medical research company’s stock after selling 9,245 shares during the quarter. CIBC Asset Management Inc’s holdings in IQVIA were worth $56,752,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Jag Capital Management LLC raised its position in shares of IQVIA by 0.4% in the 4th quarter. Jag Capital Management LLC now owns 11,401 shares of the medical research company’s stock worth $2,638,000 after acquiring an additional 49 shares in the last quarter. Laurel Wealth Advisors LLC raised its position in shares of IQVIA by 1.1% in the 3rd quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company’s stock worth $927,000 after acquiring an additional 50 shares in the last quarter. Parkside Financial Bank & Trust raised its position in shares of IQVIA by 18.1% in the 3rd quarter. Parkside Financial Bank & Trust now owns 346 shares of the medical research company’s stock worth $68,000 after acquiring an additional 53 shares in the last quarter. B. Riley Wealth Advisors Inc. grew its stake in shares of IQVIA by 1.6% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock worth $702,000 after buying an additional 56 shares during the last quarter. Finally, Greenleaf Trust grew its stake in shares of IQVIA by 1.9% in the 4th quarter. Greenleaf Trust now owns 3,154 shares of the medical research company’s stock worth $730,000 after buying an additional 58 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

IQV traded down $0.25 during midday trading on Tuesday, hitting $216.22. 655,421 shares of the company were exchanged, compared to its average volume of 988,071. The company’s 50 day simple moving average is $233.59 and its 200 day simple moving average is $229.96. The firm has a market capitalization of $39.40 billion, a price-to-earnings ratio of 29.57, a price-to-earnings-growth ratio of 2.00 and a beta of 1.54. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73.

IQVIA (NYSE:IQVGet Free Report) last posted its earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The firm had revenue of $3.74 billion for the quarter, compared to analysts’ expectations of $3.69 billion. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have commented on the company. Evercore ISI cut their target price on IQVIA from $275.00 to $250.00 and set an “outperform” rating on the stock in a research note on Friday, May 3rd. Barclays increased their target price on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Robert W. Baird dropped their price target on IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a research note on Friday, May 3rd. BTIG Research began coverage on IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price target on the stock. Finally, StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $257.57.

View Our Latest Research Report on IQVIA

About IQVIA

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVFree Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.